Research Projects

The AAL project eWare “Early Warning (by lifestyle monitoring) Accompanies Robotics Excellence” is focused on improving the lifestyle of people with dementia and their caregivers considering the extreme impact of this disease in the world. Caring for a person with dementia (PwD) can be a significant personal and emotional challenge for informal...

The four-year MICRO-THERAPY is a fully integrated interdisciplinary proposal which will develop a new area of competence in the three partners, Liverpool John Moores University, University of Rennes1 and ManRos Therapeutics. It brings together a powerful set of partners covering fully the three key aspects - microwave engineering, chemistry and...

Recent human epidemiological and animal experimentation studies have revealed that negative conditions occurring prenatally influence the appearance of metabolic and cardiovascular diseases, some of which are in turn risk factors for Alzheimer’s disease (AD). The aim of this proposal is to determine if and how early-life stress may precipitate...

IMI’s growing neurodegenerative disorders (ND) portfolio is to get a new, dynamic platform – NEURONET – that will make it easier for the many projects to exploit synergies and connect the resources and needs of the different projects. NEURONET aims to be a key enabler and mediator across the portfolio, assisting in identifying gaps, multiplying...

ProtEprobe takes advantage of the recent cutting edge developments in protein conformation control at the Malliaras group and high sensitive protein sensing using high sensitivity factor triangular silver nanoplates by the fellow. Misfolding of a protein occurs when it becomes trapped in a local potential energy minimum where the conformation...

Ageing of the European population is increasing prevalence of age-related diseases such as Alzheimer’s disease (AD). AD is considered a public health priority due to socio-economic costs and limited efficacy of current pharmacological treatments. Co-registration of electroencephalogram (EEG) and transcranial magnetic stimulation (TMS) is a novelty...

Alzheimer’s disease (AD) is a fatal neurodegenerative disease, manifested by a progressive loss of synaptic connectivity, neuronal death and memory impairment. AD affects 1 out of 10 Europeans aged over 65. There are no effective therapies for AD, in part because there is no proven molecular explanation of the steps leading from initial neuronal...

Ageing is one of the most critical risk factors for neurological and psychiatric diseases. However, the biological links between physiological ageing and pathological development are still largely unknown. A solid understanding of the biology of brain ageing will thus be a key to developing the means to treat these diseases. Since neurons in the...

Enzymes are the most efficient, specific and selective catalysts known up to date. Despite the enzyme advantages, not all synthetic processes present a natural enzyme to catalyze and accelerate the reactions. Hence, the design of new stable enzymes for those processes where no biocatalyst is known represents a major challenge for protein...

Alzheimer’s disease (AD) and other dementias affect over 7 million individuals in Europe. There is, as yet, no treatment to halt or reverse disease progression despite huge investments into research. The accumulation of the amyloid beta-peptide (Abeta), derived from the amyloid precursor protein (APP) in the brain, is a key factor in the...

Prevention of Alzheimer’s disease (AD) and dementia is a global public health priority. EURO-FINGERS builds upon the successful experiences of two multimodal prevention trials: the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) and the JPND-funded MIND-AD. The FINGER intervention trial showed that a...

Induced pluripotent stem cells (iPSC) are the cornerstone of many regenerative medicine projects, and offer researchers a powerful new approach to model and study a range of diseases. The European Bank for Induced Pluripotent Stem Cells (EBiSC) was established to provide researchers across academia and the pharmaceutical industry with disease...